Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: A nationwide series

Joint Bone Spine

Volumn 79, Issue 5, 2012, Pages 457-463

  Toussirot, Éric ^a,b,c   Houvenagel, Éric ^d   Goëb, Vincent ^e   Fouache, Damien ^e   Martin, Antoine ^f   Le Dantec, Philippe ^g   Dernis, Emmanuelle ^h   Wendling, Daniel ^a,c   Ansemant, Thiphaine ⁱ   Berthelot, Jean Marie ^j   Bader Meunier, Brigitte ^k   Kantelip, Bernadette ^b  

^a HÔPITAL SAINT JACQUES   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c Université Bourgogne Franche Comté   (France)

^d Centre Hospitalier Saint Philibert GHICL   (France)

^e UNIVERSITÉ DE ROUEN   (France)

^f Saint Brieuc Hospital   (France)

^g Rheumatology private office   (France)

^h CENTRE HOSPITALIER DU MANS   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

Crohn's disease; Inflammatory bowel disease; Paradoxical effect; TNF antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; MESALAZINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADULT; ANKYLOSING SPONDYLITIS; ANUS FISSURE; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EXPOSURE; ENDOSCOPY; ENTERITIS; ENTHESITIS; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; MOUTH ULCER; OUTCOME ASSESSMENT; PSORIASIS; PSORIATIC ARTHRITIS; RECTUM HEMORRHAGE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS; UVEITIS; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84867980671     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.10.001     Document Type: Article

References (25)

1. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized double blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
2. Fouache D., Goëb V., Massy-Guillemant N., et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondylarthropathies: a retrospective study. Rheumatology 2009, 48:761-764.
3. Immediato-Daiën C., Monnier A., Claudepierre P., et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology 2009, 48:883-886.
4. Montgommery E.A. Colon inflammatory. Biopsy interpretation of the gastrointestinal tract 2005, 213-267. Linppincott Williams and Wilkins, Riverwoods, IL 60015. E.A. Montgommery (Ed.).
5. Oh J., Arkfeld D.G., Horwitz D.A. Development of Crohn's disease in a patient taking etanercept. J Rheumatol 2005, 32:752-753.
6. Ahmad K., Rogers S. Development of Crohn's disease in a patient on etanercept for psoriasis. Br J Dermatol 2007, 157:396.
7. Song I.H., Appel H., Haibel H., et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008, 35:532-536.
8. Tsochatzis E., Vassilopoulos D., Manesis E.K., et al. First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. Scand J Gastrenterol 2007, 42:784-785.
9. Yazisiz V., Avci A.B., Erbasan F., et al. Developemnt of Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 2008, 10:953-954.
10. Elkayam O., Litinsky I., Levartovsky D., et al. The changing face of spondylarthropathies under TNF-α blockade. Open Rheumatol J 2008, 2:53-57.
11. Haraoui B., Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum 2009, 39:176-181.
12. Ruemmele F.M., Prieur A.M., Talbotec C., et al. Development of Crohn's disease during anti TNF-α therapy in a child with juvenile idiopathic arthritis. J Ped Gastroenterol Nutr 2004, 39:203-206.
13. Wiegering V., Morbach H., Dick A., et al. Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int 2010, 30:801-804.
14. Dallochio A., Canioni D., Ruemmele F., et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology 2010, 49:1694-1698.
15. Oikonomou K.A., Kapsoritakis A.N., Tsipoulos F.D., et al. Emergence of Crohn's disease in juvenile idiopathic arthritis during treatment of etanercept: a causal link or a mere coincidence?. J Gastrointestin Liver Dis 2010, 19:342.
16. Davis J.C., Van der Heijde D., Braun J., et al. Recombinant human tumor necrosis factor receptor (etanercept) fro treating ankylosing spondylitis. A randomized controlled trial. Arthritis Rheum 2003, 48:3230-3236.
17. Brandt J., Listing J., Haibel H., et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005, 44:342-348.
18. Prescott K., Costner M., Cohen S., et al. Tumor necrosis factor alpha inhibitor associated ulcerative colitis. Am J Med Sci 2007, 333:137-139.
19. Mielants H., Veys E.M., Cuvelier C., et al. The evolution of spondylarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995, 22:2279-2284.
20. Toussirot E., Wendling D. Crohn's disease associated with seropositive rheumatoid arthritis. Clin Exp Rheumatol 1997, 15:307-311.
21. Braun J., Baraliakos X., Listing J., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor α agents. Arthritis Rheum 2007, 57:639-647.
22. Gerloni V., Pontikaki I., Gattinara M., et al. Focus on adverse events of tumor necrosis factor a blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008, 67:1145-1152.
23. Marzo Ortega H., McGonagle D., O'Connor P., et al. Efficacy of etanercept for the treatment of Crohn's related spondylarthritis but not colitis. Ann Rheum Dis 2003, 62:74-76.
24. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
25. Zou J., Rudwaleit M., Brandt J., et al. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis. During treatment with etanercept. Ann Rheum Dis 2003, 62:561-564.